Cholangiocarcinoma (CCA) comprises a heterogeneous group of malignant tumours with dismal prognosis. During the last years, different studies have highlighted the key role of the immune system in the development of CCA. Although immune cells can carry out anti-tumour immune responses, they can also be influenced in the presence of
El colangiocarcinoma (CCA) es un cáncer biliar raro y heterogéneo, con una incidencia y mortalidad creciente. En este estudio planteamos la hipótesis de que el factor de transcripción KLF5 actúa como oncogén en el CCA, por lo que la inhibición de su expresión puede tener valor terapéutico. Por ello, nos
Charla: “Turning Digital Medicine into Actionable Medicine”
Rubén Armañanzas is a scientist with 20 years of experience in artificial intelligence, machine learning, bio & neuro informatics, and biomedical applications. He obtained his doctoral degree in 2009 (extraordinary doctorate award 2008/2009) at the University of the Basque Country (San Sebastián, Spain). He moved to Madrid to work at
El Biobanco Vasco en Investigación
El Biobanco Vasco es una plataforma del ámbito hospitalario, orientada a fomentar la investigación básico-clínica para facilitar la generación de herramientas para la prevención, diagnóstico y descubrimiento de dianas terapéuticas, cuyo funcionamiento asegura la calidad y el cumplimiento de las normativas éticas aplicables a la investigación. Queremos aprovechar esta oportunidad
Characterization of explants containing a bioengineered graft for improved bone regeneration
Critical-sized bone defects are defined as those that will not heal spontaneously within a patient’s lifetime. These non-union bone defects are common in cases of major orthopedic fracture and bone loss (particularly those resulting from trauma) and they have an increasing prevalence when considering the rise in osteoporosis cases. In
Protein maturation by the furin-like enzymes and resistance to anti-cancer treatments
Dr. Majid Khatib obtained his PhD from the University of Paris and completed his postdoctoral training at McGill University (Montreal, Canada). Starting in 2002, he directed his own laboratory as Scientist at the Ottawa Hospital Research Institute (OHRI), University of Ottawa (Ontario, Canada). Since 2008, he has been a research
Lugar : Subdirección de Salud Pública y Adicciones de Gipuzkoa, Avda de Navarra nº 4. Donostia- San Sebastian (Gipuzkoa).
Ponente: Alexandar Tzankov. Head of Histopathology and Autopsy Department University Hospital Basel (Basel, Switzerland).
Hora: 14:00.
Lugar: Salón de Actos del IIS Biodonostia.
Idioma: Inglés.
Ponente: Angughali Sumi, Solon Lab (Biomechanics of Morphogenesis). Cell and Developmental Biology, Centre for Genomic Regulation (CRG), Barcelona.
Hora: 13:00.
Lugar: Sala de Formación del IIS Biodonostia.
Idioma: Inglés.
Ponente: Dr. Ronald Koop. Técnico especialista en Imagen Preclínica de PerkinElmer. Ron Koop, Ph.D., is Senior Technical Application Specialist for Preclinical Imaging at PerkinElmer. He is responsible for customer support and training for PerkinElmer’s preclinical imaging portfolio in Europe. Dr. Koop holds a Ph.D. in Molecular Biology from Regensburg University and has worked many years on transcriptional regulation mechanisms at UCLA, the Institute for Molecular Biology in Marburg and the CRG in Barcelona.
Hora: 10:30.
Lugar: Sala de Formación del IIS Biodonostia.
Organizador: Plataforma de Animalario y Quirófano Experimental y Área de Oncología.
Hora: Miércoles, 15 de julio del 2015, 14:00h.
Lugar: IIS Biodonostia, Sala de Formación.
Ponente: Dr. David Brea López, Brain and Mind Research Institute, Cornell University, New York.
Hora: De 10:00 a 13:00.
Ponente: Elena Aller Arranz Ph.D. Field Application Specialist Spain & Portugal, Affymetrix.
Lugar: Sala de formación del IIS Biodonostia.
Programa:
Primera parte: Soluciones de Affymetrix para extraer lo mejor del genoma en proyectos de medicina translacional.
Segunda parte: Demostraciones reales de los software de Affymetrix Chas y TAC:
Contacto organizador: Ana Gorostidi (ana.gorostidi@biodonostia.org; 943 00 61 27).
Mark Middleton, Chair of Experimental Cancer Medicine (University of Oxford).
Chris Hatton, Director of Clinical Medicine (John Radcliffe Hospital, Oxford)
Speaker: Prof. Matías Ávila, Senior Scientist at the Division of Hepatology of the Center for Applied Medical Research (CIMA). Full Professor of Biochemistry and Molecular Biology at the University of Navarra. Associate Editor of Gut.
Time: 12:00
The best international health specialists will be present in MIHealth Forum. Industry experts will reflect on how to improve health systems in the near future.
The best international health specialists will be present in MIHealth Forum. Industry experts will reflect on how to improve health systems in the near future.
“Advances in Oncology Seminar series”
Títle: “Therapeutic and Clinical implications of the genomic landscape of breast cancer”
Date: 5th March 2014
Hour: 14:00 h.
Place: Biodonostia HRI
More information: Aleix Prat Cancer Seminars / Aleix Prat CV
LNA™-based technology: A promising tool for identifying microRNA as biomarkers for disease and toxicology studies in biofluids
Day: 17 February
Time: 12:30
Place: IIS Biodonostia
Speaker: Dr. Michael Hansen. Senior Scientist, Exiqon, Denmark.
Abstract: Seminario_microRNA
Date: February Thursday 13th
Place: Biodonostia (3rd floor)
Time: 12:00h
Dra. Naiara Beraza (CICBiogune)
Dra. Naiara Beraza performed her doctoral thesis in the Dept. of internal medicine in the University of Navarra where she investigated the role of Cardiotrophin-1, a cytokine belonging to the IL6- family, during liver injury. Next, she moved to Germany to investigate the role of the IKK complex during the progression of NASH in Prof. C. Trautwein’s lab. Her postdoctoral work uncovered the essential role of IKKg/NEMO in protecting the liver against tumorigenesis. Moreover, her work highlighted the implication of the TRAIL/NK-cell axis as a major contributor to the progression of NASH. Also, her work underlined that NEMO is essential for the regeneration of the liver and the protection against acute liver injury. Afterwards, Dr. Beraza moved to CICbioGUNE to develop her Ramon y Cajal contract. There, she has focused in further elucidating the implication of NK cells during acute liver injury, fibrogenesis and NASH progression in the context of GNMT deficiency; a pathological situation observed in cirrhotic and HCC patients. Currently, her work is focalized on Sirtuin-1 and its involvement during liver regeneration and fibrogenesis.
Title: Exome vs GWAS, the challenge of NGS in genetic
Speaker: David Otaegi (Group Leader of the Multiple Sclerosis – HRI Biodonostia)
Place: Training Room, HRI Biodonostia
Time: 13:30
“Advances in Oncology Seminar series”
Title: “Nuevas fronteras en reprogramación celular” (New frontiers in cellular reprogramming)
Speaker: Manuel Serrano. Head of Molecular Oncology Department. Spanish National Cancer Center (CNIO)
Speaker: Iñaki Osorio (Multiple Sclerosis Group Biodonostia)
The doctorate Iñaki Osorio, will abstract his thesis project.
Hour: 13:30
Room: Assembly Hall
Día: 17 de noviembre de 2013
Hora: 11:00 h – 20:00 h.
Lugar: Eureka! Zientzia Museoa.
Con Stands de empresas: IIS Biodonostia, Cita – Alzheimer, Elkargi, Bic Berrilan, Regennia, Wattio, I2Basque y Tecnalia.
Programa: FOLLETO_Digital gipuzkoa 2013
Programa: HAD Donosti
Fecha: 7 de noviembre de 2013
Hora: 16:30 h.
